Fluoroquinolone antibiotic and corticosteroid combination

This page covers all Fluoroquinolone antibiotic and corticosteroid combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA gyrase and topoisomerase IV (moxifloxacin), phospholipase A2 and other enzymes (prednisolone), DNA gyrase and topoisomerase IV, phospholipase A2.

Targets

DNA gyrase and topoisomerase IV (moxifloxacin), phospholipase A2 and other enzymes (prednisolone) · DNA gyrase and topoisomerase IV, phospholipase A2

Phase 3 pipeline (2)

• moxifloxacin/prednisolone combination · Adapt Produtos Oftalmológicos Ltda. · Ophthalmology
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while prednisolone is a corticosteroid that reduces inflammation by inhibiting phospholipase A2 and other enzymes.
• moxifloxacin 0,5% + prednisolone 1% · Adapt Produtos Oftalmológicos Ltda. · Ophthalmology
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while prednisolone is a corticosteroid that reduces inflammation by inhibiting phospholipase A2 and other pro-inflammatory enzymes.

Patent intelligence

• fluoroquinolone antibiotic and corticosteroid patent landscape — aggregated cliff calendar, attackable patents, originator estates